Lipitor Study May Influence Stroke Clinical Guidelines – NEJM Editorial
Results of a study showing that Pfizer's Lipitor reduced the overall incidence of stroke in patients with a recent stroke or transient ischemic attack is likely to encourage the adoption of statin therapy into stroke treatment guidelines, according to an editorial by David Kent (Tufts-New England Medical Center) in the Aug. 10 New England Journal of Medicine
You may also be interested in...
Pfizer is hoping to use the results of its failed torcetrapib trials as additional evidence of Lipitor's efficacy in halting progression of atherosclerosis, while competitor AstraZeneca offers new data to expand Crestor's use into early atherosclerosis
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011